Showing 2751-2760 of 3547 results for "".
Tuberous Xanthomas in the Setting of Mild Dyslipidemia
https://practicaldermatology.com/youngmd-connect/resident-resource-center/case-report-tuberous-xanthomas-record-setting-match-day-dermatology-salaries-among-highest-for-specialties/22997/Dr. Kauvar Discusses Experience with Gemini Laser
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-kauvar-discusses-experience-with-gemini-laser/19469/“Treating with the Gemini is very well accepted by patients because both components of the Gemini, the 1064 and the 532nm, are non-invasive lasers. So there's really no real downtime and no recuperation, and the results are predictable in our hands, and patients are very satisfied with their treatUnderstanding Zeltiq
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/understanding-zeltiq/21623/Practical considerations for integrating lasers and energy based devices in a dermatology practice.“Skin May Be Deep, But Dermatologists Are Superficial…”
https://practicaldermatology.com/topics/general-topics/skin-may-be-deep-but-dermatologists-are-superficial/21254/Know Your Pigmented Lesions
https://practicaldermatology.com/youngmd-connect/resident-resource-center/know-your-pigmented-lesions/23560/A diagnostic challenge and review of a rare melanocytic lesion.Biologics in Pediatric Dermatology
https://practicaldermatology.com/topics/psoriasis/biologics-in-pediatric-dermatology/23198/Younger patients are finally gaining access to a range of highly targeted treatments with lower risk profiles than their traditional alternatives.Managing Diaper Dermatitis
https://practicaldermatology.com/topics/pediatric/managing-diaper-dermatitis/20357/First-line treatment tips and a review of when to assess for an alternate diagnosis.Diversity in the Dermatology Workforce: What Can We Do?
https://practicaldermatology.com/topics/practice-management/diversity-in-the-dermatology-workforce-what-can-we-do/23057/Medicine in general lacks workforce diversity. Dermatology fares worse than other specialties. Here’s a closer look at the problem.Biologics for Psoriasis: A Status Update
https://practicaldermatology.com/topics/psoriasis/biologics-for-psoriasis-a-status-update/23006/The field has grown substantially from the early 2000s to include now a dozen innovator systemic agents, a host of biosimilars, and soon JAK Inhibitors.Complications of Biologic Therapy for Psoriasis: Part II
https://practicaldermatology.com/topics/psoriasis/complications-of-biologic-therapy-for-psoriasis-part-ii/22039/Therapeutic success requires clinicians to understand emerging and established safety concerns.